Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 19 of 19 for “"anti-CTLA-4"”.
-
Mechanistic Elucidation and Therapeutic Improvement of Anti-CTLA-4 Therapies
Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic; however, long-term benefit is limited to a subset of patients for select cancer indications. The incomplete understanding of their mechanism of action has hindered efforts at improvement, with conflicting …
-
Bhlhe40: Required For Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
… 2012). This therapy allows for the modulation of anti-tumor responses through the use of monoclonal antibodies, such as anti-CTLA-4 or anti-PD-1 that block the receptors from binding with their ligands, thus allowing for CD4<sup>+</sup> and CD8<sup>+</sup> T cell priming and activation(Wei et al., …
-
Role of the Gut Microbiome in Cancer Immunotherapy Efficacy and Side Effects
… on cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed cell death protein 1 (PD-1) blockade. The research examined how gut microbiota dysbiosis influences T cell populations in various intestinal compartments during CTLA-4 blockade therapy, the connection between specific …
-
Defining The Cooperation Between Mhc-I and Mhc-Ii Neoantigen-Driven T Cell Responses to Develop Effective Personalized Immunotherapies
<p>Immune checkpoint therapy (ICT) (e.g. anti-CTLA-4 (α-CTLA-4), anti-PD-1 (α-PD-1)) enables durable T cell-dependent anti-tumor immunity in certain cancer patients. Since a subset of patients respond to ICT, this work aims at developing a more in-depth understanding of T-cell responses to MHC …
-
Smac Mimetic and Combination Immunotherapy for the Treatment of Urothelial Cell Carcinoma
… these proteins and are being evaluated for their anti-cancer efficacy and immunomodulatory effects. Here, I adopted an orthotopic murine model of urothelial carcinoma (MB49) resistant to prominent immune-stimulating therapies BCG mycobacterium and PD-1/PD-L1 checkpoint blockade. I found treatment …
-
Understanding and Targeting The Immunosuppressive Tumor Microenvironment
<p>Immune checkpoint inhibitors (ICIs), such as anti-PD1/PD-L1 and anti-CTLA-4, have shown impressive antitumor efficacy by improving the activity of T cells. While these inhibitors work in many patients with various cancer types, they have minimal or no effect in many more patients. Mounting …
-
Εργαστηριακή μελέτη της επίδρασης της ανοσοθεραπείας στο εντερικό μικροβίωμα πειραματικού μοντέλου mus musculus με μελάνωμα
… ομάδες: ομάδα ελέγχου, μόνο ανοσοθεραπεία (anti-CTLA-4/PD-1), μόνο μελάνωμα (κύτταρα B16F10), και συνδυασμός μελανώματος με ανοσοθεραπεία. Μετά από πειραματική περίοδο 15 ημερών, συλλέχθηκαν δείγματα κοπράνων και εκχυλίστηκε μικροβιακό DNA για αλληλούχιση 16S rRNA. Εφαρμόστηκαν ειδικές …
-
Synergistic anti-tumor immune response to combination immunotherapy consisting of anti-tumor antibodies, extended half-life Interleukin-2, and other immunomodulatory agents
… on either stimulating T-cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). However, as our understanding of antitumor immune responses grows, it has become increasingly apparent that single agent …
-
Tumor Antigens Revealed by Exome Seqeuncing Drive Editing of Tumor Immunogenicity
… tumor immunogenicity and provide evidence that antigens expressed by tumors drive the destructive or sculpting actions of immunity on cancers.</p> <p>Initial studies confirmed the finding that IFN-γ is a critical mediator of cancer immunoediting. Wild type mice treated with antibodies that …
-
Preclinical Evaluation of Immunomodulatory Effects of Aurora Kinase Inhibition In Human Papillomavirus Positive Cancers
… immunogenic cell death (ICD) that would promote antitumor efficacy of immune checkpoint therapy. The current investigation focused on the effectiveness of alisertib, an Aurora Kinase A inhibitor using preclinical mouse tumor models of HPV+ cancers (mEER, TC-1, and C3.43). In vitro, alisertib …
-
Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells
… rats were examined. At the molecular level, rat CTLA-4, a receptor important for deactivating T cell responses, was examined for the expression pattern and in vitro functions. For this purpose, anti-rat CTLA-4 mAbs were generated. Consistent with the studies in mice and humans, rat CTLA-4 was …
-
Elucidating The Roles of Il-15 In The Tumor Microenvironment
… T cells and NK cells, and has been shown to have anti-tumor effects. Moreover, loss of IL-15 expression in human colorectal tumors correlates with increased risk of relapse, diminished survival, decreased density and proliferation of T cells. All together these findings suggest that IL-15 …
-
The Treatment of Solid Tumours with Complete Freund's Adjuvant
… intratumourally in an attempt to induce an anti-tumour immune response, leading to tumour regression. CFA has been used in research for decades, primarily to produce research antibodies. CFA is composed of heat-killed mycobacteria in mineral oil and surfactant, which when emulsified with an …
-
The Treatment of Solid Tumours with Complete Freund's Adjuvant
… intratumourally in an attempt to induce an anti-tumour immune response, leading to tumour regression. CFA has been used in research for decades, primarily to produce research antibodies. CFA is composed of heat-killed mycobacteria in mineral oil and surfactant, which when emulsified with an …
-
Defining the relationship between the gut microbiome and response to combination immune checkpoint blockade across cancer types
… and Cytotoxic T Lymphocyte associated protein 4 (CTLA-4) have revolutionised the treatment of many cancers, and can be used in combination for synergistic anti-tumour effect. Nevertheless, response to ICIs remain unpredictable, and we lack reliable ‘biomarkers’ to predict this a priori. Studies …
-
Modelling pancreatic cancer in vivo with patient derived organoids & humanised mouse models for the investigation of immunotherapeutic treatment response
… cancer through the activation and enhancement of anti-tumour immunity and have shown great success in the treatment of haematological cancers. However, they are limited in their ability to reach solid tumours such as PDAC. The discouraging success rate of immunotherapies in solid tumours may be …
-
NOVEL MONO-, BI- AND TRI-SPECIFIC IMMUNOMODULATORY ANTIBODIES FOR CANCER THERAPY AND TOOLS FOR OTHER THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
… of novel human immunomodulatory monoclonal antibodies targeting different ICs, with improved efficacy and safety profiles. Some novel ICIs were previously isolated in our laboratory and characterized for their biological properties. Here, they were tested in combinations to identify those …
-
Assessment of the clinical validity of ctDNA Analysis for melanoma management
… our protocol for plasma ctDNA extraction and quantification using droplet digital PCR (Chapter 2). Using this methodology, we evaluated the ctDNA detection rate in untreated BRAF mutant melanoma patients, as a potential alternative to tumour genotyping (Chapter 3), where the potential economic …
-
Studying the B and plasma cell responses to the immune checkpoint blockade treatment of cancer
… blockade (ICB) therapies targeting PD-1 and CTLA-4 have revolutionised cancer treatment. However, their efficacy is not completely understood, especially regarding their effects on anti-tumour B and plasma cell responses, which are now regarded as important components of the adaptive immune …